Kornimate/medical-research-clean huggingface dataset:
investigation of spinal posture and anthropometric characteristics of women with chronic constipation

Conditions: Chronic Constipation

Summary: the aim of this study was to compare the spinal posture and anthropometric characteristics of women with chronic constipation (cc) and healthy women.


Eligibility criteria:
inclusion criteria: * inclusion criteria for women with chronic constipation: * constipation according to rome iv criteria between the ages of 18-65 * volunteer * literacy * inclusion criteria for healthy women: * no constipation according to rome iv criteria between the ages of 18-65 * volunteer * literacy exclusion criteria: * cancer, neurological disease, serious or uncontrolled systemic or metabolic disease * being pregnant * having a mental problem that will prevent cooperation * having alarm symptoms over the age of 50 * having a diagnosis of secondary constipation * being bmi\&gt;35 * having megacolon/megarectum and inactive (lazy) bowel syndrome * having had colostomy surgery * having a history of recent abdominal surgery * having an open wound or local tumor in the abdominal region * having an abdominal hernia

Keywords: chronic constipation posture anthropometric measurement physical activity
a study evaluating the safety and tolerability of abrupt discontinuation of saredutant in patients with depression

Conditions: Depressive Disorder

Summary: the primary objective is to evaluate the safety and tolerability of abrupt discontinuation of saredutant over 1 week in outpatients with depression who completed 8 weeks of treatment with saredutant 100 mg once daily. the secondary objective is to evaluate the safety and tolerability of 8 weeks of open-label treatment with saredutant 100 mg once daily in outpatients with depression.


Eligibility criteria:
inclusion criteria: * diagnosis of major depressive disorder,single or recurrent episode, as defined by diagnostic and statistical manual of mental disorders dsm-iv criteria exclusion criteria: * total score of \<22 on the montgomery-asberg depression rating scale (madrs). * duration of the current depressive episode is less than 1 month or greater than 2 years. * total score of \<25 on the mini mental state examination (elderly patients ≥65 years only). * patients with a history or presence of bipolar disorders or psychotic disorders. * patients with alcohol dependence or abuse or substance dependence or abuse in the past 6 months except nicotine or caffeine dependence. * patients who have used the following prior to entry: benzodiazepines or sedative-hypnotics more than 2 days per week within 1 month, antipsychotics within 1 month, fluoxetine within 1 month, monoamine oxidase inhibitors within 2 weeks, other antidepressants, anxiolytics, or mood-stabilizer (lithium, anticonvulsants) within 1 week. the investigator will evaluate whether there are other reasons why a patient may not participate.

Keywords: depression antidepressive agents
early aggressive correction of severe acidosis with tris-hydroxymethylaminomethane (tham)

Conditions: Resuscitation, Trauma Patients

Summary: this study involved the medical record review of resuscitation records for all severely-injured trauma patients requiring emergent surgical intervention and significant acidosis from 2005 through 2009.

the study objective is to assess the efficacy of fluid resuscitation and treatment of acidosis in patients who were managed with use of amine buffer tham (tris-hydroxymethlaminomethane) versus those who were resuscitated with crystalloids or colloids and may have have received sodium bicarbonate for the treatment of acidosis.

Eligibility criteria:
inclusion criteria: * presence of severe traumatic injury requiring emergent surgery * peri-operative development of severe acidosis (defined arterial ph less than or equal to 7.20 or base deficit greater than or equal to 10 meq/dl) * acidosis was treated with either tham or "usual care" (defined as crystalloid either or without sodium bicarbonate) exclusion criteria: * none

Keywords: resuscitation trauma tham colloids crystalloids
a study of peg-somatropin injection to treat children of turner syndrome

Conditions: Turner Syndrome

Summary: this study aims to explore the optimal dose of pegylated recombinant human growth hormone (peg-rhgh) injection to treat children of turner syndrome (ts), preliminarily evaluate its safety and efficacy and provide scientific and reliable evidence for the medication dosage in phase 3 clinical trial.


Eligibility criteria:
inclusion criteria: * female * bone age \<12 years * karyotype: 45, x; 45, x / 46, xxqi; 45, x / 46, xxr; 45, x / 46, xx; 46, xxqi; 46, xxpi; 45, x / 47, xxx; 46, xxp-; 45, x / 46, xxp-; 46, xxq-; 45x / 46, xxq-; 45, x / 46, xx / 47, xxx, etc. (count 50 or more cells); * facial appearance and abnormalities: patients with at least one of the following signs, which include but are not limited to facial pigmented nevus, short neck, webbed neck, low posterior hairline, low-set ears, micrognathia, high-voulted arch, shield-like chest, cubitus valgus, genu valgum, short 4th and 5th metacarpals, nail dysplasia, scoliosis, ptosis and strabismus, cardiovascular abnormalities (such as aortic stenosis, bicuspid aortic valve and hypertension), reproductive abnormalities (such as primary gonadal dysfunction), renal abnormalities, thyroid hypofunction, middle ear lesion, etc. * short stature: height below -2.5sd of the mean height of the same age and gender. * pre-pubertal (tanner stage i ) patients * no history of growth hormone treatment * the subject and his/her guardian sign the informed consent (if the subject is incapable to sign the informed consent, his/her legal guardian shall sign the name of the subject instead) exclusion criteria: * subjects with abnormal liver and kidney functions (alt \> upper limit of normal value; cr \> upper limit of normal value) * subjects positive for anti-hbc, hbsag or hbeag in hepatitis b virus tests; * subjects with highly allergic constitution or allergy to proteins or investigational product or its excipient * subjects with systemic chronic disease and immune deficiency * patients diagnosed with tumor * for patients whose tumor markers exceeding normal range in combination with other information, considering as potential high risks of tumor, they may be excluded from the treatment. * patients with mental disease * subjects with impaired glucose regulation (igr) (including impaired fasting glucose (ifg) and/or impaired glucose tolerance (igt) ) or diabetes * subjects who took part in other clinical trials within 3 months * subjects who received medicines which may interfere gh secretion or gh function, or other hormones within 3 months (such as sex steroids, glucocorticoids, etc.) * other conditions which are unsuitable for this study in the opinion of the investigator.
audio vestibular assessment in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: fibromyalgia (fm) is a common rheumatic illness distinguished by chronic pain, fatigue, cognitive problems, and functional disability. however, the differences between men and women have not yet been comprehensively studied, especially after the development of the last 2016 american college of rheumatology (acr) criteria. the disease is more common and more severe in female patients according to a study on gender differences among egyptian patients (a. moshrif et al., 2023)

fibromyalgia (fm) is a common rheumatic illness distinguished by chronic pain, fatigue, cognitive problems, and functional disability. however, the differences between men and women have not yet been comprehensively studied, especially after the development of the last 2016 american college of rheumatology (acr) criteria. the disease is more common and more severe in female patients according to a study on gender differences among egyptian patients (a. moshrif et al., 2023) (fm) is a non-inflammatory chronic disease, characterized by widespread musculoskeletal pain (tuncer et al., 2021). the etiology is still unknown and (fm) is often misdiagnosed (tuncer et al., 2021).the estimated prevalence in the general population is between 2 and 11% (hulens et al., 2023). although the underling pathological mechanisms controlling the (fm) have not been determined, neuroendocrine, genetic or molecular factors can be involved (zeigelboim \& moreira, 2011).(fm) affects females between the ages of 25 to 65 years old, although it can be seen in all ages and in both sexes (fitzcharles \& yunus, 2012), it's more common in females than in males (müller et al., 2007). the main symptoms of (fm) include, muscle pain, muscle spasms, insomnia, fatigue, tension, abdominal pain, facial tenderness, sensitivity to noise and bright lights, and central nervous system abnormalities. various neurological symptoms such as tinnitus, ear fullness, vertigo, and dizziness may also be associated, regardless of the disease severity (koca et al., 2018) many patients with fm were reported to have dizziness which may attributed to hypotension and autonomic nervous system (ans) dysfunction, in this study we want to explore if dizziness and imbalance occur due to these factors only or due to a direct effect of (fm) on the vestibular system (kanjwal et al., 2010) (mohamed et al., 2021).

Eligibility criteria:
1. inclusion criteria: - age: 15-50 years. * sex: male \& female. * patients with fulfilling the criteria for the diagnosis of fm 2. exclusion criteria: patients not fulfilling the criteria for the diagnosis of fm. * other causes of snhl as meniere's disease. * other causes of conductive hearing loss (chl) as chronic suppurative otitis media csom. * other causes of collagen and connective tissue diseases. * abnormal emg. * abnormal radiological studies of the brain. * patients are receiving of ototoxic drugs.

Keywords: audiovestibular assessment, fibromyalgia
multi-center development of a novel diagnostic test for alzheimer's disease

Conditions: Alzheimer Disease; Mild Cognitive Impairment

Summary: in this multi-center study, the investigators plan to develop a simple blood-based test for early detection of alzheimer's disease (ad). the test is based on a single injection of pramlintide, an amylin analogue and fda-approved drug currently used for treatment of diabetes. the investigative team has provided evidence in humans with full-blown ad and ad-relevant mouse models that a single injection of pramlintide transiently renders the blood brain barrier (bbb) more permeable to amyloidbeta (aß) peptides, allowing their efflux from the brain compartment into the blood. this aß efflux causes a corresponding transient elevation of blood levels of aß, the magnitude of which the applicants believe is proportional to the brain amyloid load as determined by av-45 pet. the measured difference in the level of plasma aß taken just before and a short time after injection should reveal the magnitude of the transient increase in blood aß levels. supportive preliminary data comes from later stage (full-blown) ad patients with more in-depth background studies in tg2576 and 5x familial alzheimer's disease (fad) mouse models. if successful for use as an early ad biomarker (i.e., at the mild cognitive impairment (mci) stage), this could be a game-changer for both early ad diagnostics and clinical trials aimed at identifying and testing the efficacy of drugs useful for treatment of ad at early stages. if pramlintide is effective in releasing mobile pools of aß from the brain into the blood, this could also have some therapeutic potential, with the goal of reducing brain amyloid load. three groups of participants will be studied: 1) amnestic mci with or without positive ad imaging pathology, 2) probable ad with positive imaging ad pathology, and 3) controls who have normal cognition and do not have memory complaints.


Eligibility criteria:
inclusion criteria: * current research subjects at the bu , memory center va boston healthcare, or indiana university alzheimer disease center * a consensus diagnosis of probable alzheimer's disease (ad), amnestic mild cognitive impairment (mci), or control * bmi of 20-35 * probable ad subjects must be confirmed for positive ad pathology in the central nervous center (cns0 * probable ad subjects must have a designated research proxy signed before they became demented. exclusion criteria: * diabetes mellitus * gastroparesis * use of insulin, pramlintide, other injectable anti-hyperglycemic agents, such as glucagon like peptide-1 (glp-1), or oral anti-diabetic products * unexplained hypoglycemia (glucose ≤ 60 mg/dl) or hyperglycemia (glucose ≥ 126 mg/dl) pre-injection * history of stroke * seizures or use of anti-seizure medications * history of brain injury and loss of consciousness * diagnosed cerebral amyloid angiopathy (caa) * infection within 1 month

Keywords: early ad diagnosis pramlintide challenge test amyloid amyloid pet imaging csf aβ csf ptau cognitive evaluation
a study of ritonavir-boosted danoprevir (ro5190591) in combination with pegasys and ribavirin in patients with chronic hepatitis c genotype 1

Conditions: Hepatitis C, Chronic

Summary: this study will evaluate the efficacy, safety and tolerability of danoprevir (ro5190591) plus ritonavir as compared to danoprevir alone or placebo plus ritonavir in patients with chronic hepatitis c genotype 1 receiving pegasys (peginterferon alfa-2a) and ribavirin. patients in cohorts will be randomized to receive either oral doses of danoprevir, or danoprevir plus ritonavir, or placebo plus ritonavir. all patients will receive pegasys (180mcg sc once weekly) plus ribavirin (1000-1200mg/day po), with the option to continue this treatment after completion of study drug treatment. anticipated time on study treatment is up to 12 weeks.


Eligibility criteria:
inclusion criteria: * adults, 18-65 years of age * chronic hepatitis c genotype 1 * hcv treatment naïve, or without sustained virologic response on prior peg-inf/rbv treatment * body mass index (bmi) 18 - 35 kg/m2, inclusive; minimum weight 45 kg exclusion criteria: * liver cirrhosis * decompensated liver disease or impaired liver function * medical condition associated with chronic liver disease other than chronic hepatitis c * positive for hepatitis b or hiv infection at screening * history of alcohol consumption exceeding 2 standard drinks per day when averaged over the course of a given week
functional and morphologic mri in the detection of prostate cancer in patients with prior negative biopsy

Conditions: Elevated PSA; Prostate Cancer

Summary: prostate specific antigen (psa) and digital rectal exam (dre) are used to screen for prostate cancer. patients with abnormal dre or elevated psa undergo transrectal ultrasound guided biopsy (trus-bx). there are some men who have a normal trus-bx despite persistent elevated psa and may harbor occult prostate cancer. the purpose of this study is to determine if mri using an endorectal coil, and advanced mri methods called h1 mr spectroscopy (mrs) and dynamic mr perfusion imaging (dmri) can help identify and localize prostate cancer in these patients and direct repeat trus-bx to the most suspicious location in the prostate gland. 100 men, currently under observation with elevated psa but negative trus-bx will be enrolled in the study.

prostate specific antigen (psa) and digital rectal exam (dre) are used to screen for prostate cancer. patients with abnormal dre or elevated psa undergo transrectal ultrasound guided biopsy (trus-bx). there are some men who have a normal trus-bx despite persistent elevated psa and may harbor occult prostate cancer. the purpose of this study is to determine if mri using an endorectal coil, and advanced mri methods called h1 mr spectroscopy (mrs) and dynamic mr perfusion imaging (dmri) can help identify and localize prostate cancer in these patients and direct repeat trus-bx to the most suspicious location in the prostate gland. 100 men, currently under observation with elevated psa but negative trus-bx will be enrolled in the study.

Eligibility criteria:
inclusion criteria: * prior ultrasound biopsy of prostate showing no cancer or only single microfocus of cancer exclusion criteria: * contraindication to contrast enhanced endorectal coil mri
safety and efficacy of an injectable medical device to treat knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to determine whether mm-ii is effective in the treatment of osteoarthritis, in direct comparison with an approved hyaluronic acid preparation.

osteoarthritis (oa) is the commonest form of joint disease, characterized by articular cartilage degradation with an accompanying periarticular bone response and a synovial membrane inflammation. clinical manifestations of oa in the knee include pain in and around the joint, stiffness of the joint after rest, crepitus on motion and limited joint. mm-ii medical device was designed to reduce wear and lower friction in knees of osteoarthritis patients by creating a lubricating layer onto cartilage surfaces upon injection. the purpose of this study is to determine whether a medical device mm-ii is effective in the treatment of osteoarthritis, in direct comparison with an approved hyaluronic acid preparation.

Eligibility criteria:
inclusion criteria: * symptomatic unilateral knee tibiofemoral oa * radiographic evidence of knee oa of kellgren-lawrence grade ii or iii in one or both knees on a recent 3 months time x-ray * knee pain within the last 24 hours before assessment more than 40mm on vas * pain on most days in the last month exclusion criteria: * knee pain equal or more than 80mm on a 100mm vas. * pain in the contra lateral knee; more than 30mm on a 100 vas. * concomitant inflammatory joint disease (e.g. gout, rheumatoid arthritis, history of reiter's syndrome, psoriatic arthritis and ankylosing spondylitis. * any condition that may interfere with the measure of pain in the targeted knee * concomitant meaningful synovial fluid effusion * post trauma oa * gross ligamentous instability of the knee
pharmacokinetics of drospirenone only pills: a pre- and post-bariatric surgery study

Conditions: Contraception

Summary: the purpose of this study is to investigate whether bariatric surgery affects drospirenone only pills absorption

after being informed about the study and potential risks, all participants giving written informed consent who meet the eligibility requirements will take drospirenone-only pills (4 mg, once daily). between the 21st and 28th day of drospirenone taking, pharmacokinetics will be measured. pre-bariatric surgery pharmacokinetics study will be compared with post-bariatric surgery pharmacokinetics study.

Eligibility criteria:
inclusion criteria: * thai women aged 18-45 years who are obese and had an appointment for bariatric surgery at chulalongkorn hospital * need contraception * able to use non-hormonal contraception during the study * giving consent exclusion criteria: * pregnancy or history of giving birth within 3 months * breastfeeding within the 6 months * history of using dmpa within 12 months * history of using other types of hormonal birth control pills within 4 weeks * history of bilateral oophorectomy or hysterectomy * suspected ovarian tumor or pathological ovarian cyst * regular cigarette smoking * contraindications to drospirenone

Keywords: drospirenone only pills obesity bariatric surgery roux-en-y gastric bypass pharmacokinetics absorption
women's menstruation during the covid-19 pandemic

Conditions: Menstrual Irregularity; Stress Related Disorder; COVID-19 Pneumonia; Fear; Anxiety

Summary: the covid-19 crisis has rapidly become the most significant public health crisis of our times. it has particularly impacted healthcare workers (hcw) due to the over-whelming of healthcare resources, as well as a critical absence of protective equipment and risk to their own health as well as the risk of exposure to their family. all these factors have likely resulted in significant levels of stress, anxiety, and affection of the general health

during the first wave of the pandemic, overstretched healthcare systems left health workers in hard-hit countries struggling with long working hours, fatigue, and extreme psychological stress. rapidly vanishing supplies, national lockdown, and a feeding frenzy on the open market for personal protective equipment (ppe) led to shortages. healthcare workers often had to care for patients with suspected or confirmed covid-19 infection without proper training or adequate ppe. this contributed to an increased risk to healthcare workers during the initial phase of the pandemic. study methods: this is a retrospective cross-sectional study that will be conducted among healthcare professionals working in the obstetrics and gynecology department, fayoum university fayoum, egypt. a survey-based study will be conducted between january 15 and march 1, 2022, using the database of fayoum university. a self-administered online survey consisting of 80 questions was developed.

Eligibility criteria:
inclusion criteria: * all obstetrics and gynecology department healthcare workers who were or had been resident, physicians or consultant physicians, nurses, and paramedical healthcare active during the covid-19 pandemic period at a designated fayoum university hospital, regardless of gender, age, experience, and duration of employment. exclusion criteria: * exclusion criteria: 1. physicians who were retired or did not currently work in a designated covid-19 hospital. 2. physicians from other specialties 3. physicians were on leave during the pandemic for various reasons.

Keywords: covid-19 work-related stress health care worker survey menstrual irregularity
comparison of naloxone pharmacokinetics

Conditions: Opioid-use Disorder

Summary: intranasal (in) naloxone administration is an effective alternative to intravenous (iv) or intramuscular (im) naloxone by emergency medical services for opioid overdoses and has been used successfully for this purpose as reported in clinical observational studies and a randomized controlled trial. most of the published clinical studies concerning in administration used an improvised kit of 2 mg naloxone/2 ml saline and a mucosal atomizer device (mad), which is not fda-approved for this indication. pharmacokinetic (pk) data using these kits is not available in the published literature. this study is designed to determine the pk of naloxone following one and two in administrations using the improvised kits compared to 2 and 4 mg delivered in using the fda-approved narcan nasal spray device and 2 mg administered im using the evzio autoinjector.


Eligibility criteria:
inclusion criteria: * males and females 18 to 55 years of age, inclusive * provide written informed consent * bmi ranging from 18 to 32 kg/m2, inclusive * adequate venous access * no clinically significant concurrent medical conditions determined by medical history, physical examination, clinical laboratory examination, vital signs, and 12-lead ecg * male subjects must agree to use an acceptable method of contraception with female partners as well as not to donate sperm from the screening visit until 90 days after the last study drug administration * female subjects of childbearing potential must agree to use an acceptable method of birth control from the start of screening until 30 days after the last study drug administration. oral contraceptives are prohibited * agree not to ingest alcohol, drinks containing xanthine \>500 mg/day (e.g., coca cola®, coffee, tea, etc.), or grapefruit/grapefruit juice or participate in strenuous exercise 72 hours prior to admission through the last blood draw of the study exclusion criteria: * contact site directly for more information